Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. - Wikidata - wikimedia - TriplyDB

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

http://www.wikidata.org/entity/Q35978349

about

Statin-induced diabetes: incidence, mechanisms, and implications Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study.Stroke Risk Factors, Genetics, and Prevention.[Choosing wisely recommendations in cardiology].Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data.Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial.Challenges and opportunities in accessing trial data: an example from statin primary prevention trials.Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence Role of Statin Drugs for Polycystic Ovary Syndrome.Time to improve statin prescription guidelines in low-risk patients?Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved?[Management of different cardiovascular risk factors with a combination tablet (polypill)].Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2 Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk Optical Coherence Tomography to Evaluate Plaque Burden and Morphology in Patients With Takotsubo Syndrome.Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.High Quality Statin Trials Support the 2013 ACC/AHA Cholesterol Guidelines After HOPE-3: The Multi-Ethnic Study of Atherosclerosis.A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk.Providing innovative solutions in a single pill: Servier's portfolio in hypertension.Clinical relevance for lowering C-reactive protein with statins.What to say and how to say it: effective communication for cardiovascular disease prevention.Pleiotropic Effects of Statins on the Cardiovascular System.Comprehensive efforts to increase adherence to statin therapy.The Unchartered Frontier: Preventive Cardiology Between the Ages of 15 and 35 Years.Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.Inflammation, venous thromboembolism, and what we can do about it.Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease 'Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?' No, but we can improve risk communication metrics.Risk Factors Of Heart Disease in Nurses.Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Statins alone or polypill for primary prevention of cardiovascular diseases.

P2860

Q26740677-1784E8AA-925C-42DC-9DE5-06C2EEF1BB28 Q28551905-876550E1-6A2D-47B6-9EDA-A279CE5D38DC Q30234586-8AF11040-7CFD-4F87-91C9-99FE059CE056 Q30238633-F4B2D5FC-21A4-4ACC-B21D-C2CD442DFD6F Q30313178-5F3903B2-15BE-4010-9A6D-E35F6A9C1937 Q31133434-90D298B5-06FD-4FB4-A349-AC41588C1DBD Q33390806-ACB39B28-21C6-4860-A0C9-5EBE667382DE Q33622465-A0F8D3C8-0C73-4521-B652-40703177ADB3 Q33675377-2C86FDEA-6721-45F8-9101-3F5DB6CE2A6B Q33716327-42EC27CB-26CD-4FF2-AFC3-13B30956AB7D Q33811585-BFF8BC1B-BE5E-4C26-9547-92614EBD2065 Q36193205-CFB701AA-9749-4BE4-BDF7-2A6452FD84F6 Q36322893-DEE49F5E-3381-42E8-ADEF-F7E6A46F3458 Q37236445-EBF02399-0E0E-454E-9338-5B8F1905D67C Q37298595-066E8649-1665-4722-94D9-DA20964BAAE8 Q37556331-389D0440-86F1-4975-A0F1-DBC6133FCBC0 Q38376542-577CC370-4CF0-4312-9095-1429AE65C626 Q38430383-B81C2F79-F275-4810-8583-7BF8991F87B5 Q38658832-BE643C6D-7CC6-4DBD-AF1C-0184FDE95CF8 Q38690757-EB712FF1-DA91-4686-A47B-FDE5C8831BC7 Q38716505-205F8D2D-9C15-47AD-9CA3-82AA60359377 Q38721111-CF5C5BE5-FF65-44CE-8824-970CDFF5C221 Q38786058-8C576CB3-4288-4E32-8406-312DDD282DF4 Q38825508-2F61F38E-2671-4F81-B61D-FD60982301E4 Q38833140-C0974700-0628-4C2A-8875-89F58C51AB34 Q38880500-05B17E87-364E-4B30-931E-6B09E938BF1F Q38900547-B4865EA6-3D9E-417A-86DF-78EAF3B58E20 Q39069187-3B4C36EA-B1D2-4C67-B3D3-694DEABADD9F Q39080414-955D9DB5-D2B9-42AB-B8B9-0E24AC83C457 Q39132747-72D7C8DF-9409-4F26-9C92-C00CDA4CAF5D Q39148923-73373CB5-424D-4F42-B4CE-040BB3118864 Q39320394-D8E2B998-3BC4-42EC-9492-CA230DA2BA3A Q39420208-39FE7BEB-D8BD-44D0-9A7E-FFCA1739DC8F Q40131379-D4C24A6C-EB4E-42AB-815A-19E9901A0B27 Q40194229-6A4EF265-AF07-4680-8418-AB397E1B321A Q40340206-B5DD58BF-C032-4570-A070-0AAB12E839F8 Q40642191-73F88D76-A364-4E77-ADE7-1CE1BE69FF0D Q41516001-E4E06E15-9F5E-41ED-84AD-CCA1F7802AC5 Q41689452-D0DF735F-DDEE-44F4-B109-503DA00F782B Q42356981-74AAB187-4EE4-4D29-B5E7-88016B409735

P2860

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

http://www.wikidata.org/entity/Q35978349

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@ast

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

type

label

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@ast

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

prefLabel

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@ast

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

P1433

Q35978349-DC011208-6573-4828-ABF8-0A54ADE17308

P1476

Q35978349-DE75E994-B3A4-4AEE-BD35-262D655EB54A

P2093

Q35978349-0A8FB0A6-EF57-4012-BC5D-89832364F8A7

Q35978349-0F2A7139-B97B-4292-ADCE-DE8DB5AE9BAB

Q35978349-227A8D42-42D3-4AB2-AEE4-12A952A4931F

Q35978349-2C2D5063-D6DD-482C-B88E-4B52343CD877

Q35978349-3B4B52BE-8DF2-40F7-A58F-6A99EDEF6C1D

Q35978349-531ACABC-A7F2-488A-A12A-1CEFC75765BA

Q35978349-5CFE5FE3-C6A1-4A8D-85F3-EF66CE2919A3

Q35978349-6B30197C-838C-4B8D-9B87-B198E8F6389D

Q35978349-81092A1A-F7CE-40FF-A697-16E8EEF8CABC

Q35978349-947ADF2F-B41F-4B9F-B45A-982D5410241D

P304

Q35978349-41673ECE-ABB4-46D8-80B2-7D2BFC6FD3FA

P31

Q35978349-A5FD5FF2-5086-4B22-B23C-9A32EBF304CF

P356

Q35978349-3F37F284-DEBA-46B7-8356-48606542B50A

P407

Q35978349-3BF650D2-9F88-435D-80AD-E881E2FCCE21

P433

Q35978349-72E56528-95C7-4536-8C80-52DE0FFC08AF

P478

Q35978349-DAE37906-5BD4-4A89-BAB6-0E6BAF394C41

P50

Q35978349-0F4D3EA2-2092-4CE8-937F-5923ECE45348

Q35978349-811C7C23-1D00-4AA8-AFC5-F98ECB8E2A2B

Q35978349-B724ED54-3BAE-4380-9CAC-E8C914AAE6E0

Q35978349-BAD71E8E-8516-4314-BA83-90A2CBC20FDC

Q35978349-E5B81311-261C-4A8C-9C66-BFB5A1B1C25C

Q35978349-F17EE183-7274-4263-806A-E842671286F7

Q35978349-FF222194-FCE7-4439-B815-D308301A2623

P577

Q35978349-FEFF9437-D7EB-4A04-AC81-69B6711C2EDF

P698

Q35978349-5F7B1415-51AE-46E2-8203-38F139BB7A81

P921

Q35978349-7673A5D2-5EC7-448A-9C50-17194C1036EB

P356

P1433

The New England Journal of Medicine

P1476

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

P2093

Alexander Parkhomenko

http://www.w3.org/2001/XMLSchema#string

Alvaro Avezum

http://www.w3.org/2001/XMLSchema#string

Antonio Dans

http://www.w3.org/2001/XMLSchema#string

Basil S Lewis

http://www.w3.org/2001/XMLSchema#string

Christopher M Reid

http://www.w3.org/2001/XMLSchema#string

Denis Xavier

http://www.w3.org/2001/XMLSchema#string

Eva Lonn

http://www.w3.org/2001/XMLSchema#string

Gregorio Sanchez-Vallejo

http://www.w3.org/2001/XMLSchema#string

HOPE-3 Investigators

http://www.w3.org/2001/XMLSchema#string

Hyejung Jung

http://www.w3.org/2001/XMLSchema#string

P304

2021-2031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1600176

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Gilles Dagenais

P577

2016-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27040132

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease